Immutep Limited Is A Clinical Stage Biotechnology Company Focused On Developing Innovative Immunotherapies That Target The Lymphocyte Activation Gene 3Lag 3Pathwayheadquartered In Sydneyaustraliaand Leipziggermanyimmutep Is Publicly Traded On Nasdaq And The Australian Securities Exchange The Company Specializes In Creating Therapies For Cancer And Autoimmune Diseases By Leveraging The Lag 3 Immune Control Mechanismits Product Pipeline Includes Eftilagimod Alphaimp321 A Recombinant Protein For Cancer Treatmentand Imp731A Monoclonal Antibody For Autoimmune Diseaseswhich Has Been Licensed To Glaxosmithklineother Products Include Imp701Imp761And Lag525All Targeting Lag 3 For Various Therapeutic Applicationsimmutep S Partnerships With Major Pharmaceutical Companies Like Glaxosmithkline And Novartis Underscore Its Collaborative Approach In Advancing Immunotherapy Solutions
